Anavex Life Sciences Corp (AVXL)

[XenaLives]

She is being funded by MFF apparently - historical post:

I have no idea what is going on with this post. Mike is showing that Veronica Francardo, PhD will be presenting a poster at this year's MJFF Parkinson's Disease Therapeutics Conference this Oct. 30.

The grant was given to Nilsson, which really goes to the lab she oversees at Lund.

http://www.lunduniversity.lu.se/lucat/group/v1000356

Francardo most likely specializes in this type of research so Nilsson co-authors the paper with her as per the poster at the World Parkinson Congress 2016.

http://www.anavex.com/investigating-the-potential-neurorestorative-effects-of-a-clinical-sigma-1-receptor-agonist-in-a-mouse-model-of-parkinsons-disease/

Francardo is the lead author of the poster with Nilsson part of it as well and it shows that research was supported by the MJFF. And yes, MJFF is a partner with the World Parkinson Coalition that organizes that conference so I don't believe that Francardo will be presenting the exact same piece she did then.

These two have co-authored many papers over the years as well so I don't accept your assertion that because Francardo is presenting that it has nothing to do with MJFF grant given to Anavex and Nilsson.

http://portal.research.lu.se/portal/en/persons/veronica-francardo(9c206658-28b7-4a7c-a4e3-2f199ca7618a)/publications.html

I'm still waiting for your rebuttal as to IND's don't include trial design BTW.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134048187

polarbear77 Tuesday, 08/22/17 05:56:30 PM
Re: plexrec post# 116645 0
Post #
116646
of 190090
The Anavex train indeed Plex. Looks like they could be on track as well for Parkinson's trial readout in advance of Dr Francardo's presentation in May 2018 regarding a2-73 Parkinson's results.

Found her statements below to be fairly definitive and unambiguous re her testing to date. It seems the MJFF grant funds are being put to good use here.

GLTAL

Excerpted below from Dr Francardo [who is an independent researcher with grant funds from the Michael J. Foundation and has been studying the sigma-1 receptor for many years and publishing on the topic since at least 2011 (thanks again for pointing that out OFP)]:

"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."

https://www.michaeljfox.org/foundation/researchers.php?id=1841
Veronica Francardo, PhD
Assistant Professor, Department of Experimental Medical Science BMC F11 at Lund University
Location: Lund, Sweden

Veronica Francardo received her undergraduate training at the University of Trieste, Italy, where she graduated in Medical Biotechnologies. Since 2007, Veronica is a researcher at Lund University, Sweden, where she obtained her PhD degree in Neurobiology under the supervision of Prof Angela Cenci-Nilsson. Veronica Francardo is currently Assistant Professor in the group of Prof. Angela Cenci-Nilsson and carries out pre-clinical research on animal models of Parkinson’s disease and post-mortem human brain tissue. The main interest of her work is to test and develop potential new therapies for Parkinson’s disease and related disorders."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839